Literature DB >> 15882940

RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling.

Michael O Chaney1, W Blaine Stine, Tyler A Kokjohn, Yu-Min Kuo, Chera Esh, Afroza Rahman, Dean C Luehrs, Ann Marie Schmidt, David Stern, Shi Du Yan, Alex E Roher.   

Abstract

In the AD brain, there are elevated amounts of soluble and insoluble Abeta peptides which enhance the expression of membrane bound and soluble receptor for advanced glycation end products (RAGE). The binding of soluble Abeta to soluble RAGE inhibits further aggregation of Abeta peptides, while membrane bound RAGE-Abeta interactions elicit activation of the NF-kappaB transcription factor promoting sustained chronic neuroinflammation. Atomic force microscopy observations demonstrated that the N-terminal domain of RAGE, by interacting with Abeta, is a powerful inhibitor of Abeta polymerization even at prolonged periods of incubation. Hence, the potential RAGE-Abeta structural interactions were further explored utilizing a series of computational chemistry algorithms. Our modeling suggests that a soluble dimeric RAGE assembly creates a positively charged well into which the negative charges of the N-terminal domain of dimeric Abeta dock.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882940     DOI: 10.1016/j.bbadis.2005.03.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  35 in total

1.  Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.

Authors:  Hongliang Zong; Angelina Madden; Micheal Ward; Mark H Mooney; Christopher T Elliott; Alan W Stitt
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 2.  Complexity of danger: the diverse nature of damage-associated molecular patterns.

Authors:  Liliana Schaefer
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

Review 3.  Role of RAGE in Alzheimer's Disease.

Authors:  Zhiyou Cai; Nannuan Liu; Chuanling Wang; Biyong Qin; Yingjun Zhou; Ming Xiao; Liying Chang; Liang-Jun Yan; Bin Zhao
Journal:  Cell Mol Neurobiol       Date:  2015-07-15       Impact factor: 5.046

4.  RAGE: the beneficial and deleterious effects by diverse mechanisms of actions.

Authors:  Sun-Ho Han; Yoon Hee Kim; Inhee Mook-Jung
Journal:  Mol Cells       Date:  2011-01-18       Impact factor: 5.034

Review 5.  Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity.

Authors:  Charles W Frevert; Jessica Felgenhauer; Malgorzata Wygrecka; Madalina V Nastase; Liliana Schaefer
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

6.  Solution structure of the soluble receptor for advanced glycation end products (sRAGE).

Authors:  Zsuzsa Sárkány; Teemu P Ikonen; Frederico Ferreira-da-Silva; Maria João Saraiva; Dmitri Svergun; Ana Margarida Damas
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

7.  Association between the RAGE G82S polymorphism and Alzheimer's disease.

Authors:  Keshen Li; Dawei Dai; Bin Zhao; Lifen Yao; Songpo Yao; Binyou Wang; Ze Yang
Journal:  J Neural Transm (Vienna)       Date:  2009-11-10       Impact factor: 3.575

8.  Association of the RAGE G82S polymorphism with Alzheimer's disease.

Authors:  Jonny Daborg; Malin von Otter; Annica Sjölander; Staffan Nilsson; Lennart Minthon; Deborah R Gustafson; Ingmar Skoog; Kaj Blennow; Henrik Zetterberg
Journal:  J Neural Transm (Vienna)       Date:  2010-06-22       Impact factor: 3.575

9.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

10.  Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.

Authors:  Emmanuel Sturchler; Arnaud Galichet; Mirjam Weibel; Estelle Leclerc; Claus W Heizmann
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.